Your browser doesn't support javascript.
loading
Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study.
Liu, Fuquan; Ning, Zhenyuan; Liu, Yanna; Liu, Dengxiang; Tian, Jie; Luo, Hongwu; An, Weimin; Huang, Yifei; Zou, Jialiang; Liu, Chuan; Liu, Changchun; Wang, Lei; Liu, Zaiyi; Qi, Ruizhao; Zuo, Changzeng; Zhang, Qingge; Wang, Jitao; Zhao, Dawei; Duan, Yongli; Peng, Baogang; Qi, Xingshun; Zhang, Yuening; Yang, Yongping; Hou, Jinlin; Dong, Jiahong; Li, Zhiwei; Ding, Huiguo; Zhang, Yu; Qi, Xiaolong.
Afiliación
  • Liu F; CHESS Group, Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Ning Z; CHESS Group, Hepatic Hemodynamic Lab, Institute of Hepatology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China; School of Biomedical Engineering, Southern Medical University, Guangzhou, China.
  • Liu Y; CHESS Group, Hepatic Hemodynamic Lab, Institute of Hepatology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Liu D; Xingtai People's Hospital, Xingtai Institute of Cancer Control, Xingtai, China.
  • Tian J; Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
  • Luo H; Department of General Surgery, The Third Xiangya Hospital of Central South University, Changsha, China.
  • An W; Department of Radiology, 302 Hospital of PLA, Beijing, China.
  • Huang Y; CHESS Group, Hepatic Hemodynamic Lab, Institute of Hepatology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Zou J; CHESS Group, Hepatic Hemodynamic Lab, Institute of Hepatology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Liu C; CHESS Group, Hepatic Hemodynamic Lab, Institute of Hepatology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Liu C; Department of Radiology, 302 Hospital of PLA, Beijing, China.
  • Wang L; CHESS Group, Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Liu Z; Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Qi R; Department of General Surgery, 302 Hospital of PLA, Beijing, China.
  • Zuo C; Xingtai People's Hospital, Xingtai Institute of Cancer Control, Xingtai, China.
  • Zhang Q; Xingtai People's Hospital, Xingtai Institute of Cancer Control, Xingtai, China.
  • Wang J; Xingtai People's Hospital, Xingtai Institute of Cancer Control, Xingtai, China.
  • Zhao D; Department of Radiology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
  • Duan Y; Department of Radiology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Peng B; Department of Hepatobiliary Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Qi X; Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China.
  • Zhang Y; Department of Gastroenterology and Hepatology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
  • Yang Y; Center for Therapeutic Research of Hepatocarcinoma, 302 Hospital of PLA, Beijing, China.
  • Hou J; CHESS Group, Hepatic Hemodynamic Lab, Institute of Hepatology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Dong J; Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
  • Li Z; Department of General Surgery, 302 Hospital of PLA, Beijing, China; Department of Hepatobiliary Surgery, The Third People's Hospital of Shenzhen, Shenzhen, China.
  • Ding H; Department of Gastroenterology and Hepatology, Beijing You'an Hospital, Capital Medical University, Beijing, China. Electronic address: dinghuiguo@ccmu.edu.cn.
  • Zhang Y; School of Biomedical Engineering, Southern Medical University, Guangzhou, China. Electronic address: yuzhang@smu.edu.cn.
  • Qi X; CHESS Group, Hepatic Hemodynamic Lab, Institute of Hepatology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China; Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijin
EBioMedicine ; 36: 151-158, 2018 Oct.
Article en En | MEDLINE | ID: mdl-30268833
ABSTRACT
Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations. However, hepatic venous pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG≥10 mm Hg) is invasive and therefore not suitable for routine clinical practice. This study aims to develop and validate a radiomics-based model as a noninvasive method for accurate detection of CSPH in cirrhosis. The prospective multicenter diagnostic trial (CHESS1701, ClinicalTrials.gov identifier NCT03138915) involved 385 patients with cirrhosis from five liver centers in China between August 2016 and September 2017. Patients who had both HVPG measurement and contrast-enhanced CT within 14 days prior to the catheterization were collected. The noninvasive radiomics model, termed rHVPG for CSPH was developed based on CT images in a training cohort consisted of 222 consecutive patients and the diagnostic performance was prospectively assessed in 163 consecutive patients in four external validation cohorts. rHVPG showed a good performance in detection of CSPH with a C-index of 0·849 (95%CI 0·786-0·911). Application of rHVPG in four external prospective validation cohorts still gave excellent performance with the C-index of 0·889 (95%CI 0·752-1·000, 0·800 (95%CI 0·614-0·986), 0·917 (95%CI 0·772-1·000), and 0·827 (95%CI 0·618-1·000), respectively. Intraclass correlation coefficients for inter- and intra-observer agreement were 0·92-0·99 and 0·97-0·99, respectively. A radiomics signature was developed and prospectively validated as an accurate method for noninvasive detection of CSPH in cirrhosis. The tool of rHVPG assessment can facilitate the identification of CSPH rapidly when invasive transjugular procedure is not available.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores / Tomografía Computarizada por Rayos X / Hipertensión Portal / Cirrosis Hepática Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: EBioMedicine Año: 2018 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores / Tomografía Computarizada por Rayos X / Hipertensión Portal / Cirrosis Hepática Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: EBioMedicine Año: 2018 Tipo del documento: Article País de afiliación: China